Q3 2024 United Therapeutics Corp Earnings Call Transcript
In 2025 we expect FDI action on our recently submitted pre market approval application for our centralized long evaluation systems or see less ex-vivo lung perfusion technology.
Beyond our record-setting commercial performance, we expect a steady stream of clinical data readouts and regulatory actions through the next 36 months, setting our company up well for continued growth through the balance of the decade.
Our revolution wave is also making tangible progress toward reality. With our Phase one study for Mirel, liver E lap now underway the first clinical study of a bioengineered organ alternative.
We expect data from this initial safety study in 2025. Also within our revolution way, we recently received feedback from the FDA regarding our IND for new kidney 10 gene, added xeno kidney and we expect to track to file our IND shortly for what will be the first clinical study of xeno organ.
We look forward to sharing more details on our clinical trial design and commercial
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |